Clinical Trial

Development of Microbial Metabolism Gene Tests for Facilitating Precision Health and Preventive Medicine-Evaluation of TMAO Production in Human Body From High-carnitine Diet by Fecal Gbu Gene Testing

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 8, 2026 (before its estimated June 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
The risk of cardiovascular diseases from red meat consumption varies among individuals due to variations in gut microbiota. L-carnitine in red meat can be converted to Trimethylamine n-oxide (TMAO) in the body by certain bacteria. Not everyone experiences a significant increase in TMAO levels after consuming carnitine. Gut microbiota differences are observed between high and low TMAO producers. The presence of the γ-butyrobetaine utilization (gbu) gene in gut microbiota is linked to TMAO production. This clinical research aims to determine if the gbu gene can predict TMAO levels after intaking a large amount of red meat.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-22.
Trial Details
NCT Number NCT07322575
Lead Sponsor National Taiwan University Hospital
Conditions Gut Dysbiosis for TMAO Production From Red Meat Consumption
Enrollment 65 participants
Start Date 2026-01-15
Primary Completion 2026-06-20 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-08